home / stock / nmlsf / nmlsf news

NMLSF News and Press, Nova Mentis Life Science Corp

Stock Information
Company Name: Nova Mentis Life Science Corp
Stock Symbol: NMLSF
Market: OTC
Website: novamentis.ca
Menu
NMLSF NMLSF Quote NMLSF Short NMLSF News NMLSF Articles NMLSF Message Board
Get NMLSF Alerts

News, Short Squeeze, Breakout and More Instantly...
NMLSF - Nova Mentis Announces Change of Directors

Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company") announces the appointment of Steve Loutskou to the Company's Board of Directors, effective February 23, 2024. Mr. Loutskou, a seas...
NMLSF - Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group

Vancouver, British Columbia--(Newsfile Corp. - November 3, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroin...

NMLSF - Nova Mentis Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome

Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinf...

NMLSF - Nova Mentis to Enter mRNA AI Diagnostics Business

Vancouver, British Columbia--(Newsfile Corp. - April 26, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinfl...
NMLSF - Nova Mentis Begins Recruitment in First-of-its-Kind Health Canada Psilocybin Trial

Vancouver, British Columbia--(Newsfile Corp. - April 18, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinfl...

NMLSF - Nova Mentis Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial

Vancouver, British Columbia--(Newsfile Corp. - April 11, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinfl...

NMLSF - Nova Mentis Provides Corporate Update and 2023 Outlook

Vancouver, British Columbia--(Newsfile Corp. - April 5, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinfla...
NMLSF - Novel Therapeutic Solutions are Needed as Autism Rates Increase

Vancouver, British Columbia--(Newsfile Corp. - March 29, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinfl...

NMLSF - Nova Mentis Granted Health Canada Section 56 Exemption to Begin Psilocybin Clinical Trial

Vancouver, British Columbia--(Newsfile Corp. - February 14, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroi...

NMLSF - Nova Mentis Life Science appoints executive chairman

Biotechnology company Nova Mentis Life Science ( OTCQB:NMLSF ) appointed Derek Ivany executive chairman. Ivany has been a long-term shareholder of the company. The move comes after Steve Feldman resigned from the board. Source: Press Release For further de...
Next 10